Plain-English translation of NCT07516457 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing Hydrogel OA 2%, a gel that is injected directly into the knee joint to help relieve osteoarthritis pain. Researchers want to see if the treatment is safe and well-tolerated, and whether it actually helps reduce pain and improve how well people's knees function over time.
Many people with knee osteoarthritis have pain that limits their daily activities, and current treatments don't work for everyone. This trial is exploring whether this new gel injection could be a helpful option for people whose knees don't respond well to other treatments.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection of the gel directly into your knee joint. After the injection, you would be monitored for safety and asked to report any side effects or changes in your pain over the next 13 weeks, with follow-up visits and assessments extending up to 12 months. The study also tracks how well your knee feels and functions during this time, using simple tests and questionnaires about your pain and daily activities.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Belgium
Sponsor
Allegro NV/SA
Enrollment target
~20 participants
Started
April 2026
Primary completion
December 2026
Age range
35 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kris Van den Cruys
Allegro NV/SA
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.